Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NVS
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
NVS
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

NVS Price Prediction Next Week

Technical Analysis

Based on recent price action, NVS shows a bullish trend in the short term, with the stock closing at $99.97 on January 24, 2025. The stock has formed higher lows and higher highs over the past few trading sessions.

Key technical levels:

  • Resistance: $100.18 (January 23 high)
  • Support: $98.12 (January 22 low)
  • Fibonacci resistance: $99.93
  • Fibonacci support: $97.79

The RSI reading of 52.60 indicates neutral momentum, suggesting room for further upside. The MACD indicator shows a value of -0.35, indicating some bearish divergence that needs to be monitored.

News Analysis

Recent positive catalysts include:

  • Partnership with Isomorphic Labs for AI-driven drug development
  • Potential market opportunities in biologics sector with $400 billion market size projection

However, there are some concerns:

  • Recent pullback from Cytokinetics deal
  • General market volatility amid interest rate uncertainty

Price Forecast for Next Week

Based on technical analysis and news sentiment:

  • Bullish case (60% probability): Break above $100.18 could push price to $101.65 (Fibonacci R3)
  • Bearish case (40% probability): Break below $98.12 could see price test $97.79 (Fibonacci S1)

Trading Recommendation

SELL with target entry at current levels ($99.97):

  • Short-term target: $97.79
  • Stop loss: $101.65
  • Risk/Reward ratio: 1:1.2

Rationale:

  1. Bearish MACD divergence
  2. Price approaching key resistance level
  3. RSI showing neutral momentum without strong bullish conviction
  4. Recent failed M&A activities could pressure the stock

The stock is likely to experience some profit-taking after the recent uptrend, providing a short-term trading opportunity to the downside.

Technical Analysis

Based on recent price action, NVS shows a bullish trend in the short term, with the stock closing at $99.97 on January 24, 2025. The stock has formed higher lows and higher highs over the past few trading sessions.

Key technical levels:

  • Resistance: $100.18 (January 23 high)
  • Support: $98.12 (January 22 low)
  • Fibonacci resistance: $99.93
  • Fibonacci support: $97.79

The RSI reading of 52.60 indicates neutral momentum, suggesting room for further upside. The MACD indicator shows a value of -0.35, indicating some bearish divergence that needs to be monitored.

News Analysis

Recent positive catalysts include:

  • Partnership with Isomorphic Labs for AI-driven drug development
  • Potential market opportunities in biologics sector with $400 billion market size projection

However, there are some concerns:

  • Recent pullback from Cytokinetics deal
  • General market volatility amid interest rate uncertainty

Price Forecast for Next Week

Based on technical analysis and news sentiment:

  • Bullish case (60% probability): Break above $100.18 could push price to $101.65 (Fibonacci R3)
  • Bearish case (40% probability): Break below $98.12 could see price test $97.79 (Fibonacci S1)

Trading Recommendation

SELL with target entry at current levels ($99.97):

  • Short-term target: $97.79
  • Stop loss: $101.65
  • Risk/Reward ratio: 1:1.2

Rationale:

  1. Bearish MACD divergence
  2. Price approaching key resistance level
  3. RSI showing neutral momentum without strong bullish conviction
  4. Recent failed M&A activities could pressure the stock

The stock is likely to experience some profit-taking after the recent uptrend, providing a short-term trading opportunity to the downside.

NVS Similar Chart Price Prediction

The price of NVS is predicted to go up -19.33%, based on the high correlation periods with CMRE. The similarity of these two price pattern on the periods is 95.16%.

stocks logo

NVS

stocks logo

CMRE

Down: -19.33%Similarity: 95.16%

NVS Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030

Year

NVS Price Forecast($)

Potential Return(%)

2025

98.040

0.410

2026

110.000

12.660

2027

120.000

22.900

2028

130.000

33.140

2029

140.000

43.300

2030

140.000

43.300

What is NVS stock price prediction 2025 ?

NVS stock is currently trading at $98.04. Based on technical analysis, the Fibonacci resistance levels suggest a potential upside to $99.98, while RSI indicates the stock is oversold, supporting a bullish outlook. Considering Novartis' strong pipeline developments, including SMA treatments, the stock could reach $105–$110 by the end of 2025, driven by growth in innovative therapies.

What is NVS stock price prediction 2026 ?

NVS stock is predicted to reach approximately $110 by 2026. This projection is based on Novartis' consistent revenue growth, advancements in its pharmaceutical pipeline, and favorable market sentiment. However, potential risks include regulatory challenges and broader market volatility.

What is NVS stock price prediction 2027 ?

NVS stock is predicted to reach approximately $120 by 2027, driven by consistent revenue growth, strong pipeline developments like OAV101 IT, and a stable dividend yield. The company's focus on innovative treatments and expansion in key markets supports long-term growth. However, macroeconomic factors and competition could influence the actual outcome.

What is NVS stock price prediction 2028 ?

NVS stock price in 2028 is projected to reach approximately $130, driven by consistent growth in its pharmaceutical pipeline and strong performance in emerging markets. Novartis' advancements in gene therapy, such as OAV101 IT for SMA, and its focus on innovative treatments are expected to sustain revenue growth. However, macroeconomic factors and competition in the healthcare sector could influence this estimate.

What is NVS stock price prediction 2029 ?

Price prediction for NVS stock in 2029 is $140-$160. This estimate is based on Novartis' strong pipeline, including gene therapies like OAV101, and consistent revenue growth in pharmaceuticals. However, risks such as litigation and market competition could moderate gains.

What is NVS stock price prediction 2030 ?

NVS stock price prediction for 2030 is estimated to reach $140-$160, driven by consistent revenue growth, strong R&D pipeline, and expanding market share in innovative therapies. Novartis' focus on high-margin drugs and gene therapies positions it well for long-term growth. However, macroeconomic factors and competition could influence the exact trajectory.

NVS Revenue Forecast

NVS EPS Forecast

NVS FAQs

What is bull’s view on NVS?

NVS stock is currently trading near $96.71. The bullish view anticipates a potential rise to $100, supported by a favorable risk-benefit profile from its SMA gene therapy (OAV101 IT) and strong pipeline developments. Additionally, Novartis's strategic focus on innovative treatments and share buybacks enhances investor confidence.

What is bear's view on NVS?

NVS stock currently trades near $95. The bear's view stems from concerns about valuation, as its P/E ratio is higher than peers, and limited near-term growth catalysts despite positive SMA trial results. Additionally, broader market sentiment and potential regulatory hurdles could weigh on the stock.

What is NVS revenue forecast for next quarter？

The market consensus for NVS's revenue in the upcoming quarter is projected to be approximately $12.67B USD.

What is NVS eps forecast for next quarter？

The market consensus for NVS's eps in the upcoming quarter is projected to be approximately $1.83 USD.

NVS VS S&P500

Novartis' solid late-stage pipeline should propel long-term growth. The company should launch several new drugs during the next several years in critical therapeutic areas such as rare diseases and oncology.

Novartis recently divested its Roche share, yielding over $20 billion, which provides the firm with increased options to re-deploy capital including share buybacks.

Novartis' research and development focuses on areas of unmet medical need, which should yield several innovative therapies with strong pricing power.

Ask Intellectia about NVS

NVS Analyst's Forecast

Hans Engel

Erste Group

Strong Buy → Hold

Price Target

n/a

Upside

0%

Erste Group downgraded Novartis to Hold from Buy.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2024 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free